European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ventana Medical Systems, Inc
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
Provision of an archival FFPE tumour sample
Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
Participants who received at least 6 cycles of PBC during the induction phase of their current line of treatment.
Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
Participants with non-progressive disease upon completion of PBC in their current line of treatment.
Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).
You may not be if
Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)
